US20090149391A1 - Novel antimicrobial bolisin peptides - Google Patents

Novel antimicrobial bolisin peptides Download PDF

Info

Publication number
US20090149391A1
US20090149391A1 US12/289,180 US28918008A US2009149391A1 US 20090149391 A1 US20090149391 A1 US 20090149391A1 US 28918008 A US28918008 A US 28918008A US 2009149391 A1 US2009149391 A1 US 2009149391A1
Authority
US
United States
Prior art keywords
bol
peptide
peptides
effective amount
bolisin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/289,180
Inventor
Cornelia Liepke
Susann Baxmann
Knut Adermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IPF Pharmaceuticals GmbH
Original Assignee
IPF Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IPF Pharmaceuticals GmbH filed Critical IPF Pharmaceuticals GmbH
Priority to US12/289,180 priority Critical patent/US20090149391A1/en
Publication of US20090149391A1 publication Critical patent/US20090149391A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Definitions

  • the invention relates to peptides having a highly effective antimicrobial activity, processes for the preparation thereof, and the use thereof.
  • WO 97/35877 describes the occurrence and purification of antibiotic peptides from cow's milk
  • PCT/EP 01/06518 describes the recovery of antimicrobial peptides from human placenta extract and from bovine thymus extract, and their application.
  • Glucosin is a fragment of the bovine mitochondrial proteolipid comprising 17 amino acids, and it inhibits the growth of pathogenic microorganisms in low-salt nutrient media.
  • R 1 represents an amino group (NH 2 ), an amino acid or a peptide having up to 10 amino acids, and R 2 represents COOH, CONH 2 , an amino acid or a peptide having up to 10 amino acids;
  • Z represents an aromatic amino acid (W, Y, F), preferably tyrosine (Y) or an amino acid mono- or polyhalogenated at the aromatic moiety, preferably tyrosine (Y);
  • X 1 represents arginine (R) or an aromatic amino acid (W, Y, F), preferably tryptophan (W) or an amino acid mono- or polyhalogenated at the aromatic moiety, preferably tryptophan;
  • X 2 represents serine (S), a basic amino acid (R, K), preferably arginine (R), or an aromatic amino acid (W, Y, F), preferably tryptophan (W) or an amino acid mono- or polyhalogenated at the aromatic moiety, preferably tryptophan;
  • X 3 represents threonine (T), a hydrophobic amino acid (I, V, A, L) or arginine (R);
  • X 4 represents aspartic acid (D), proline (P), a basic amino acid (K, R), preferably arginine (R), or an aromatic amino acid (W, Y, F), preferably tryptophan (W) or an amino acid mono- or polyhalogenated at the aromatic moiety, preferably tryptophan; and
  • B represents a basic amino acid (K, R).
  • the invention also relates to derivatives and/or fragments of the peptides according to the invention having antimicrobial activity, especially the derivatives and/or fragments which are amidated, acylated, acetylated, alkylated, sulfated, phosphorylated, halogenated, especially halogenated at aromatic amino acid side chains, glycosylated, oxidized, modified by esterification or lactone formation, and/or cyclized.
  • Halogenated peptides are preferably halogenated at aromatic residues of amino acid side chains.
  • the amino acids are designated with the one-letter code.
  • the peptides according to the invention have the following sequences:
  • R 1 -ZIX 3 X 1 BX 3 RX 2 ADBRX 2 BALB-R 2 (Sequence ID Nos.: 2, 4, 8, 12, 13, 15)
  • R 1 -ZIX 3 X 1 BX 3 RX 2 APBRX 2 BALB-R 2 (Sequence ID No.: 11)
  • R 1 -ZIX 3 X 1 BX 3 RX 2 ABBRX 2 BALB-R 2 (Sequence ID Nos.: 1, 3, 5, 6, 7, 9, 10, 18, 21-24, 28, 29, 31, 32, 35, 38, 41, 45, 47, 48, 51)
  • R 1 -ZIX 3 X 1 BX 3 RX 2 AZBRX 2 BALB-R 2 (Sequence ID Nos.: 14, 16, 17, 19, 20, 25-27, 30, 33, 34, 36, 37, 42-44, 46, 49, 50, 52, 53, 54)
  • R 1 -ZIX 3 X 1 BX 3 RX 2 TZBRX 2 BALB-R 2
  • Preferred peptides of the invention are listed in Table 1.
  • the invention also relates to their derivatives and/or fragments having antimicrobial activity, especially the derivatives and/or fragments which are amidated, acylated, acetylated, alkylated, sulfated, phosphorylated, halogenated, glycosylated, oxidized, modified by esterification or lactone formation, and/or cyclized.
  • the invention comprises the peptides modified by esterification or lactone formation as well as the peptides according to the invention which have been reacted at a free amino group with activated polyoxyalkylene glycol or a conjugate of a polyoxyalkylene glycol and, for example, a fatty acid.
  • activated polyoxyalkylene glycol or a conjugate of a polyoxyalkylene glycol and, for example, a fatty acid Preferred are fatty acids having a chain length of from 12 to 18 carbon atoms and polyoxyethylene as the polyoxyalkylene glycol having a chain length of from 2 to 100. More preferred are activated polysorbate esters and their derivatives.
  • the peptide conjugates are prepared for improving the pharmacological properties of the peptides.
  • the peptides may also comprise the corresponding D-amino acids instead of the natural L-amino acids, as well as iminoamino acids and rare amino acids, such as hydroxylysine, homoserine and ornithine.
  • the invention comprises the retro, inverso and retro-inverso peptides.
  • “Retro peptides” means the peptides according to the invention having a reverse amino acid sequence
  • inverso peptides means the peptides according to the invention which consist of D-amino acids
  • “retro-inverso peptides” means those peptides which have a reverse amino acid sequence formed from D-amino acids.
  • the invention also relates to peptide mimetics of the peptides according to the invention. These are characterized by a modification of one or more peptide bonds, for example, by a reverse peptide bond or by an ester bond.
  • the bolisin analogues according to the invention are cationic peptides having antibiotic activity.
  • the bolisin analogues contain at least 9 and at most 37 amino acid residues, preferably not more than 20 amino acid residues.
  • the peptide analogues of bolisin according to the invention have a clearly increased antimicrobial activity.
  • the peptides described in the present invention also effectively inhibit the growth of pathogenic germs in nutrient media which have a physiological salt concentration and therefore, in contrast to the naturally occurring bolisin, can be used for a wide variety of applications. Human pathogenic germs with antibiotic resistance are also killed at low peptide concentrations.
  • fragments there may be used, in particular, N-terminally or C-terminally truncated peptides, but also peptides in which individual amino acids are deleted, preferably not more than 10% of the amino acids.
  • the invention relates to these fragments to the extent where they have antimicrobial properties. “Antimicrobial properties” of the fragment means that the fragment has at least 50% of the activity of the parent peptide, i.e., at most requires double the inhibitory concentration.
  • the test microorganisms employed are either Staphylococcus aureus or Escherichia coli , depending on against which microorganism the peptide exhibits a better activity. The microorganisms are characterized as follows:
  • Staphylococcus aureus Gram-positive cocci, ATCC 25923;
  • Escherichia coli Gram-negative rods, ATCC 25922.
  • the invention also comprises nucleic acids which code for the peptides according to the invention, and vectors and plasmids which contain such nucleic acids.
  • the invention also relates to a medicament which contains one or more peptides according to the invention.
  • the peptides according to the invention are suitable for the treatment of diseases caused by misplaced microbial colonizations, such as infections, inflammations, microbially induced tumors, microbially caused degenerative diseases, diarrheic diseases, colics, deviations in the oral, intestinal and vaginal floras, caries, sepsis, toxic shock conditions.
  • the misplaced microbial colonization may be caused, for example, by bacteria, fungi, yeasts, protists, viruses, mycoplasmas, filariae and/or plasmodiums. They may be employed in both acute and chronic diseases of humans and animals.
  • the peptides according to the invention are preferably used in medicinal formulations.
  • the medicinal formulation contains one or more of the peptides according to the invention, or a physiologically acceptable salt of the peptides.
  • Medicinal formulations can contain pharmaceutically usual auxiliary agents which contribute, for example, to the solubility, stability or sterility of the medicament or increase the efficiency of uptake into the body.
  • antibiotic substances may be contained, for example, from the group of penicillins, cephalosporins, carbacephems, cephamycins, carbapenems, quinolones, tetracyclines, aminoglycosides, macrolides, glycopeptides, chloroamphenicols, glycylcyclines, licosamides, fluoroquinolones and peptide antibiotics.
  • the form and composition of the medicament which contains the peptides depends on the route of administration.
  • galenic formulations and application forms are selected in which the peptides arrive at the target site in a non-degraded condition.
  • the peptides can be administered enterally, parenterally, intranasally, orally and by inhalation.
  • the peptides are packaged with an injection preparation either as a solution or as a lyophilizate for dissolution immediately before use.
  • the peptides can be, for example, injected intravenously, injected or implanted intraperitoneally, injected or implanted subcutaneously, injected intradermally, injected or implanted intramuscularly, injected intrathecally, inhaled (aerosol, spray) or applied topically (e.g., creams, ointments, eyedrops, eardrops, shampoos).
  • Bolisin analogues can be administered locally as injection, drops, spray, tablets, suppositories, cream, ointments, gel etc. It is possible to perform the administration as a bolus or repeatedly over a period of time.
  • the dose of the peptides to be administered depends on the indication and the application of particular derivatives.
  • the peptides according to the invention are employed in amounts of from 0.1 to 100 mg/kg of body weight.
  • the invention also relates to a diagnostic agent which contains peptides or nucleic acids according to the invention.
  • the peptides according to the invention may also be used as additives to food-stuffs. They may be used in the preparation of foodstuffs as auxiliary agents, especially for foodstuffs which are prepared by fermentation and other bacterial processes.
  • the preparations according to the patent are natural preservatives.
  • Further possibilities of the application of the peptides according to the invention are the use as disinfectants for all situations in which microorganisms are not desired. Examples thereof are the application for the surface disinfection or as a coating of medicinal products, air filters and requisites, such as clothing and jewels.
  • Medical products means all medical auxiliaries which are applied to the patient, such as implants, prostheses, stents, tubes, cannulas, catheters, synthetic vascular systems, artificial heart valves and needles.
  • the term “medicinal products” further includes containers for the storage of blood or blood components as well as containers for organ shipping etc. Further, it is possible to use the peptides in water processing, or as a component of shampoos and soaps, as food additives, cosmetic preservatives, additives for the preservation of cell culture media etc. and as a plant protection agent.
  • the peptide synthesis of bolisin analogues is based on the standard method of solid-phase Fmoc strategy.
  • an ABI 433 A Synthesizer (Applied Biosystems, Rothstadt, Germany) was used.
  • An Fmoc-Lys(boc) Wang resin served as the solid phase.
  • the individual coupling steps were checked to ensure that each amino acid was incorporated in a high yield.
  • Peptides were cleaved from the resin with 94% trifluoroacetic acid (TFA), 3% ethanedithiol and 3% water and subsequently purified by chromatography.
  • RP HPLC reverse phase HPLC
  • a preparative RP C18 column (PrepPAK 500 C18, 47 ⁇ 300 mm) served as the solid phase, and acetonitrile served as eluant (mobile solvent A: 0.07% TFA in water; mobile solvent B: 80% acetonitrile/0.07% TFA in water).
  • eluant mobile solvent A: 0.07% TFA in water
  • mobile solvent B 80% acetonitrile/0.07% TFA in water
  • the peptides were eluted from the solid phase by the gradient method (increment of 0.5% mobile solvent B per min in the eluant) and detected at a wavelength of 215 nm.
  • the synthetic peptides were analyzed by mass spectrometry. The purity of the peptides was checked by capillary zone gel electrophoresis and analytical reverse-phase HPLC (purity ⁇ 95%). The amino acid sequence of the peptides was verified by automated Edman degradation.
  • the bolisin analogues of the present invention were examined for their suitability as antibiotic therapeutical agents by means of various biological tests.
  • the chemically synthesized peptides were examined for their antimicrobial effectiveness against three Gram-positive and three Gram-negative bacterial strains as well as against a yeast.
  • Gram-positive Staphylococcus aureus ATCC 25923 Enterococcus faecalis ATCC 51299 (vancomycin-resistant) Streptococcus pneumoniae DSM 11865 (penicillin-resistant)
  • Gram-negative Escherichia coli ATCC 25922 Pseudomonas aeruginosa ATCC 9027 Klebsiella pneumoniae ATCC 10031
  • Yeast Candida albicans ATCC 10231
  • the antibiotic activity of bolisin analogues was examined by determining the minimum inhibition concentration.
  • the minimum inhibition concentration of an analogue designates the lowest peptide concentration which is required to inhibit the growth of microorganisms completely after an incubation time of 18 ⁇ 2 h. This method allows to obtain a quantitative result about the antimicrobial potency of the peptides.
  • These examinations were performed by analogy with the recommendations (M7-A3) edited by the NCCLS (National Committee for Clinical Laboratory Standards) by applying a dilution test in a liquid medium using chemically synthesized peptides (peptide sequences according to claims 1 to 3 ).
  • Mueller Hinton Broth was used as the test medium according to the NCCLS recommendations unless indicated otherwise.
  • Table 2 shows the antimicrobial activity of the peptide analogues, which is clearly improved as compared to the parent peptide bolisin.
  • the minimum inhibition concentrations are stated in [ ⁇ g/ml].
  • the peptides according to the invention effectively inhibit the growth of both Gram-positive and Gram-negative bacteria as well as of yeasts.
  • Human pathogens such as Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae , were effectively killed.
  • bacteria having an existing antibiotic-resistance such as Streptococcus pneumoniae (penicillin-resistant) and Enterococcus faecalis (vancomycin-resistant).
  • the potency of action of the bolisin analogues is manifoldly better than that of the parent peptide bolisin.
  • microorganisms 1-6 the minimum inhibition concentration of the peptides against Gram-positive and Gram-negative microorganisms. Tryptic Soy Broth (3 g/l) with an addition of salt in physiological concentration (150 mM sodium chloride) was used as the test medium. Table 3 shows the antimicrobial activity of the peptide analogues in a salt-containing medium, which is also significantly improved over that of the parent peptide bolisin.
  • Bolisin analogues having a good antimicrobial activity against at least one of the seven strains of microorganisms tested were selected for checking their cytotoxic activity.
  • the ability of antimicrobial peptides to deposit on plasma membranes and permeabilize them is considered the mechanism of action of these substances. It is desirable that bacterial membranes are selectively damaged, whereas the cells of the host should remain unaffected.
  • the hemolysis test is used in which the lysing and thus toxic activity of the peptides against red blood cells (erythrocytes) is examined. The procedure for determining the hemolytic activity of the peptides was performed by analogy with Helmerhorst et al. (Helmerhorst et al., 1999, FEBS Lett. 449: 105-110).
  • Hemolysis [%] [ A 450 nm (peptide) ⁇ A 450 nm (negative control)]/[ A 450 nm (1% Tween 20) ⁇ A 450 nm (negative control)]*100
  • TSB medium with 287 mM glucose served as the test medium.
  • the isotonic glucose concentration is to prevent non-specific hemolysis in a hypotensive medium (osmoprotection).
  • peptides according to the invention exhibit no or but moderate lytic properties against erythrocytes.
  • “Moderate lytic properties” means a lysis of less than 30% of the erythrocytes for the application of antimicrobially effective peptide concentrations.
  • FIG. 1 shows that bolisin analogues in antimicrobially effective concentrations do not cause any hemolysis worth mentioning ( ⁇ 5%). Even at high concentrations (500 ⁇ g/ml), only a moderate lytic activity can be established ( ⁇ 30%). For comparison, the hemolytic activity of the antimicrobial peptide MBI-28 (Gough et al., 1996, Infect. Immun. 64(12): 4922-7) was plotted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)

Abstract

The invention relates to antibiotically effective peptides which are prepared for medical and commercial use by using biotechnological methods and chemical synthesis. The antibiotically effective peptides can be used in a suitable galenic formulation as medicaments/animal medicaments, food additives or as preservatives for the prevention of microbial contaminations of cosmetics, medical products and requisites.

Description

  • The invention relates to peptides having a highly effective antimicrobial activity, processes for the preparation thereof, and the use thereof.
  • It is known that naturally occurring peptides may be antibiotically effective. Thus, WO 97/35877 describes the occurrence and purification of antibiotic peptides from cow's milk, and PCT/EP 01/06518 describes the recovery of antimicrobial peptides from human placenta extract and from bovine thymus extract, and their application.
  • One of the peptides purified from bovine thymus extract is bolisin (PCT/EP 01/06518, SEQ ID No. 5). Bolisin is a fragment of the bovine mitochondrial proteolipid comprising 17 amino acids, and it inhibits the growth of pathogenic microorganisms in low-salt nutrient media.
  • It is an object of the invention to provide bolisin-based peptides which have a particularly high specific activity under different conditions. It is also an object of the invention to provide peptides which inhibit the growth of microorganisms in environments with physiological salt concentrations and at the same time have as low as possible a hemolytic activity.
  • Surprisingly, this object is achieved by providing peptides of the sequence

  • R1-ZX3X3X1BX3RX2X3X4BRX2BX3X3B—R2,
  • wherein
  • R1 represents an amino group (NH2), an amino acid or a peptide having up to 10 amino acids, and R2 represents COOH, CONH2, an amino acid or a peptide having up to 10 amino acids;
  • Z represents an aromatic amino acid (W, Y, F), preferably tyrosine (Y) or an amino acid mono- or polyhalogenated at the aromatic moiety, preferably tyrosine (Y);
  • X1 represents arginine (R) or an aromatic amino acid (W, Y, F), preferably tryptophan (W) or an amino acid mono- or polyhalogenated at the aromatic moiety, preferably tryptophan;
  • X2 represents serine (S), a basic amino acid (R, K), preferably arginine (R), or an aromatic amino acid (W, Y, F), preferably tryptophan (W) or an amino acid mono- or polyhalogenated at the aromatic moiety, preferably tryptophan;
  • X3 represents threonine (T), a hydrophobic amino acid (I, V, A, L) or arginine (R);
  • X4 represents aspartic acid (D), proline (P), a basic amino acid (K, R), preferably arginine (R), or an aromatic amino acid (W, Y, F), preferably tryptophan (W) or an amino acid mono- or polyhalogenated at the aromatic moiety, preferably tryptophan; and
  • B represents a basic amino acid (K, R).
  • The invention also relates to derivatives and/or fragments of the peptides according to the invention having antimicrobial activity, especially the derivatives and/or fragments which are amidated, acylated, acetylated, alkylated, sulfated, phosphorylated, halogenated, especially halogenated at aromatic amino acid side chains, glycosylated, oxidized, modified by esterification or lactone formation, and/or cyclized. Halogenated peptides are preferably halogenated at aromatic residues of amino acid side chains. The amino acids are designated with the one-letter code.
  • Preferably, the peptides according to the invention have the following sequences:
  • R1-ZIX3X1BX3RX2ADBRX2BALB-R2 (Sequence ID Nos.: 2,
    4, 8, 12, 13, 15)
    R1-ZIX3X1BX3RX2APBRX2BALB-R2 (Sequence ID No.: 11)
    R1-ZIX3X1BX3RX2ABBRX2BALB-R2 (Sequence ID Nos.: 1,
    3, 5, 6, 7, 9, 10,
    18, 21-24, 28, 29,
    31, 32, 35, 38, 41,
    45, 47, 48, 51)
    R1-ZIX3X1BX3RX2AZBRX2BALB-R2 (Sequence ID Nos.:
    14, 16, 17, 19, 20,
    25-27, 30, 33, 34,
    36, 37, 42-44, 46, 49,
    50, 52, 53, 54)
    R1-ZIX3X1BX3RX2TZBRX2BALB-R2 (Sequence ID No.: 55)

    wherein X3 represents a hydrophobic amino acid (I, V) or arginine (R), and R1, R2, Z, X1, X2 and B have the meanings as stated above. Preferred peptides of the invention are listed in Table 1. The invention also relates to their derivatives and/or fragments having antimicrobial activity, especially the derivatives and/or fragments which are amidated, acylated, acetylated, alkylated, sulfated, phosphorylated, halogenated, glycosylated, oxidized, modified by esterification or lactone formation, and/or cyclized.
  • The invention comprises the peptides modified by esterification or lactone formation as well as the peptides according to the invention which have been reacted at a free amino group with activated polyoxyalkylene glycol or a conjugate of a polyoxyalkylene glycol and, for example, a fatty acid. Preferred are fatty acids having a chain length of from 12 to 18 carbon atoms and polyoxyethylene as the polyoxyalkylene glycol having a chain length of from 2 to 100. More preferred are activated polysorbate esters and their derivatives. The peptide conjugates are prepared for improving the pharmacological properties of the peptides.
  • In addition to the derivatives mentioned, the peptides may also comprise the corresponding D-amino acids instead of the natural L-amino acids, as well as iminoamino acids and rare amino acids, such as hydroxylysine, homoserine and ornithine. Further, the invention comprises the retro, inverso and retro-inverso peptides. “Retro peptides” means the peptides according to the invention having a reverse amino acid sequence, “inverso peptides” means the peptides according to the invention which consist of D-amino acids, and “retro-inverso peptides” means those peptides which have a reverse amino acid sequence formed from D-amino acids.
  • The invention also relates to peptide mimetics of the peptides according to the invention. These are characterized by a modification of one or more peptide bonds, for example, by a reverse peptide bond or by an ester bond.
  • The bolisin analogues according to the invention are cationic peptides having antibiotic activity. The bolisin analogues contain at least 9 and at most 37 amino acid residues, preferably not more than 20 amino acid residues.
  • The peptide analogues of bolisin according to the invention have a clearly increased antimicrobial activity. The peptides described in the present invention also effectively inhibit the growth of pathogenic germs in nutrient media which have a physiological salt concentration and therefore, in contrast to the naturally occurring bolisin, can be used for a wide variety of applications. Human pathogenic germs with antibiotic resistance are also killed at low peptide concentrations.
  • As the fragments, there may be used, in particular, N-terminally or C-terminally truncated peptides, but also peptides in which individual amino acids are deleted, preferably not more than 10% of the amino acids. The invention relates to these fragments to the extent where they have antimicrobial properties. “Antimicrobial properties” of the fragment means that the fragment has at least 50% of the activity of the parent peptide, i.e., at most requires double the inhibitory concentration. The test microorganisms employed are either Staphylococcus aureus or Escherichia coli, depending on against which microorganism the peptide exhibits a better activity. The microorganisms are characterized as follows:
  • Staphylococcus aureus: Gram-positive cocci, ATCC 25923;
  • Escherichia coli: Gram-negative rods, ATCC 25922.
  • The invention also comprises nucleic acids which code for the peptides according to the invention, and vectors and plasmids which contain such nucleic acids.
  • The invention also relates to a medicament which contains one or more peptides according to the invention.
  • The peptides according to the invention are suitable for the treatment of diseases caused by misplaced microbial colonizations, such as infections, inflammations, microbially induced tumors, microbially caused degenerative diseases, diarrheic diseases, colics, deviations in the oral, intestinal and vaginal floras, caries, sepsis, toxic shock conditions. The misplaced microbial colonization may be caused, for example, by bacteria, fungi, yeasts, protists, viruses, mycoplasmas, filariae and/or plasmodiums. They may be employed in both acute and chronic diseases of humans and animals.
  • The peptides according to the invention are preferably used in medicinal formulations. The medicinal formulation contains one or more of the peptides according to the invention, or a physiologically acceptable salt of the peptides. Medicinal formulations can contain pharmaceutically usual auxiliary agents which contribute, for example, to the solubility, stability or sterility of the medicament or increase the efficiency of uptake into the body. Further, other antibiotic substances may be contained, for example, from the group of penicillins, cephalosporins, carbacephems, cephamycins, carbapenems, quinolones, tetracyclines, aminoglycosides, macrolides, glycopeptides, chloroamphenicols, glycylcyclines, licosamides, fluoroquinolones and peptide antibiotics.
  • The form and composition of the medicament which contains the peptides depends on the route of administration. Preferably, galenic formulations and application forms are selected in which the peptides arrive at the target site in a non-degraded condition. The peptides can be administered enterally, parenterally, intranasally, orally and by inhalation. Preferably, the peptides are packaged with an injection preparation either as a solution or as a lyophilizate for dissolution immediately before use. The peptides can be, for example, injected intravenously, injected or implanted intraperitoneally, injected or implanted subcutaneously, injected intradermally, injected or implanted intramuscularly, injected intrathecally, inhaled (aerosol, spray) or applied topically (e.g., creams, ointments, eyedrops, eardrops, shampoos). Bolisin analogues can be administered locally as injection, drops, spray, tablets, suppositories, cream, ointments, gel etc. It is possible to perform the administration as a bolus or repeatedly over a period of time.
  • The dose of the peptides to be administered depends on the indication and the application of particular derivatives. Preferably, the peptides according to the invention are employed in amounts of from 0.1 to 100 mg/kg of body weight.
  • The invention also relates to a diagnostic agent which contains peptides or nucleic acids according to the invention.
  • The peptides according to the invention may also be used as additives to food-stuffs. They may be used in the preparation of foodstuffs as auxiliary agents, especially for foodstuffs which are prepared by fermentation and other bacterial processes. The preparations according to the patent are natural preservatives. Further possibilities of the application of the peptides according to the invention are the use as disinfectants for all situations in which microorganisms are not desired. Examples thereof are the application for the surface disinfection or as a coating of medicinal products, air filters and requisites, such as clothing and jewels. “Medicinal products” means all medical auxiliaries which are applied to the patient, such as implants, prostheses, stents, tubes, cannulas, catheters, synthetic vascular systems, artificial heart valves and needles. The term “medicinal products” further includes containers for the storage of blood or blood components as well as containers for organ shipping etc. Further, it is possible to use the peptides in water processing, or as a component of shampoos and soaps, as food additives, cosmetic preservatives, additives for the preservation of cell culture media etc. and as a plant protection agent.
    • EXAMPLES Chemical Synthesis of Bolisin Analogues
  • The peptide synthesis of bolisin analogues is based on the standard method of solid-phase Fmoc strategy. For the automated synthesis, an ABI 433 A Synthesizer (Applied Biosystems, Weiterstadt, Germany) was used. An Fmoc-Lys(boc) Wang resin served as the solid phase. During the peptide synthesis, the individual coupling steps were checked to ensure that each amino acid was incorporated in a high yield. Peptides were cleaved from the resin with 94% trifluoroacetic acid (TFA), 3% ethanedithiol and 3% water and subsequently purified by chromatography.
  • For the chromatographic purification, reverse phase (RP) HPLC was applied. A preparative RP C18 column (PrepPAK 500 C18, 47×300 mm) served as the solid phase, and acetonitrile served as eluant (mobile solvent A: 0.07% TFA in water; mobile solvent B: 80% acetonitrile/0.07% TFA in water). At a flow rate of 40 ml/min, the peptides were eluted from the solid phase by the gradient method (increment of 0.5% mobile solvent B per min in the eluant) and detected at a wavelength of 215 nm.
  • The synthetic peptides were analyzed by mass spectrometry. The purity of the peptides was checked by capillary zone gel electrophoresis and analytical reverse-phase HPLC (purity ≧95%). The amino acid sequence of the peptides was verified by automated Edman degradation.
  • The amino acid sequences of the synthesized bolisin analogues according to the invention are stated in Table 1 using the one-letter code.
  • TABLE 1
    Name SEQ ID No. Sequence
    BOL-6 1 YIVYKIRSARKRSKALK
    BOL-7 2 YIVYKIRSADKRRKALK
    BOL-11 3 YIVYKRRSARKRSKALK
    BOL-12 4 YIVYKRRSADKRRKALK
    BOL-13 5 YIVYKIRSARKRRKALK
    BOL-14 6 YIRYKIRSARKRRKALK
    BOL-15 7 YIVYKRRSARKRRKALK
    BOL-16 8 YIRYKRRSADKRRKALK
    BOL-17 9 YIRYKIRSARKRRKALK
    BOL-18 10 YIRYKRRSARKRRKALK
    BOL-21 11 YIVYKIRSAPKRSKALK
    BOL-25 12 YIVWKIRSADKRSKALK
    BOL-27 13 YIVYKIRWADKRSKALK
    BOL-29 14 YIVYKIRSAWKRSKALK
    BOL-30 15 YIVYKIRSADKRWKALK
    BOL-44 16 YIVYKIRSAWKRRKALK
    BOL-45 17 YIVYKIRSAWKRWKALK
    BOL-46 18 YIVYKIRSARKRWKALK
    BOL-47 19 YIVYKIRWAWKRSKALK
    BOL-48 20 YIVYKIRWAWKRRKALK
    BOL-49 21 YIVYKIRWARKRSKALK
    BOL-50 22 YIVYKIRWARKRRKALK
    BOL-51 23 YIVYKIRWARKRWKALK
    BOL-52 24 YIVYKIRRARKRRKALK
    BOL-53 25 YIVYKIRRAWKRSKALK
    BOL-54 26 YIVYKIRRAWKRRKALK
    BOL-55 27 YIVYKIRRAWKRWKALK
    BOL-56 28 YIVYKIRSAKKRKKALK
    BOL-57 29 YIVYKIRSAKKRWKALK
    BOL-58 30 YIVYKIRSAWKRKKALK
    BOL-59 31 YIVYKIRWAKKRKKALK
    BOL-60 32 YIVYKIRWAKKRWKALK
    BOL-61 33 YIVYKIRWAWKRKKALK
    BOL-67 34 YIVYKIRSAWKRWKAL
    BOL-68 35 YIVYKIRSARKRWKAL
    BOL-69 36 YIVYKIRSAWKRRK
    BOL-70 37 YIVYKIRSAWKRWK
    BOL-71 38 YIVYKIRSARKRWK
    BOL-72 39 YIVYKIRWARKRRKAL
    BOL-73 40 YIVYKIRWARKRRK
    BOL-74 41 YIVWKIRSARKRRKALK
    BOL-75 42 YIVWKIRSAWKRSKALK
    BOL-79 43 YIVRKIRSAWKRWKALK
    BOL-80 44 YIVRKIRSAWKRRKALK
    BOL-81 45 YIVWKIRSARKRWKALK
    BOL-82 46 YIVWKIRSAWKRWKALK
    BOL-83 47 YIVRKIRSARKRRKALK
    BOL-84 48 KYIVYKIRSARKRRKALK
    BOL-85 49 KYIVYKIRSAWKRSKALK
    BOL-86 50 KYIVYKIRSAWKRRKALK
    BOL-87 52 KYIVYKIRWARKRRKALK
    BOL-91 52 YIVYKIRFAFKRSKAL
    BOL-92 53 YIVYKIRFAFKRRKAL
    BOL-93 54 YIVYKIRWAWKRSKAL
    BOL-97 55 YIVYKIRWTWKRSKAL
    BOL-103 56 KLAKRRKWAWRIKYVIY
  • Examination of the Antimicrobial Effectiveness of Bolisin Analogues
  • The bolisin analogues of the present invention were examined for their suitability as antibiotic therapeutical agents by means of various biological tests. Thus, the chemically synthesized peptides were examined for their antimicrobial effectiveness against three Gram-positive and three Gram-negative bacterial strains as well as against a yeast.
  • The following microorganisms were used:
  •
    Gram-positive: Staphylococcus aureus ATCC 25923
    Enterococcus faecalis ATCC 51299
    (vancomycin-resistant)
    Streptococcus pneumoniae DSM 11865
    (penicillin-resistant)
    Gram-negative: Escherichia coli ATCC 25922
    Pseudomonas aeruginosa ATCC 9027
    Klebsiella pneumoniae ATCC 10031
    Yeast: Candida albicans ATCC 10231
  • The antibiotic activity of bolisin analogues was examined by determining the minimum inhibition concentration. The minimum inhibition concentration of an analogue designates the lowest peptide concentration which is required to inhibit the growth of microorganisms completely after an incubation time of 18±2 h. This method allows to obtain a quantitative result about the antimicrobial potency of the peptides. These examinations were performed by analogy with the recommendations (M7-A3) edited by the NCCLS (National Committee for Clinical Laboratory Standards) by applying a dilution test in a liquid medium using chemically synthesized peptides (peptide sequences according to claims 1 to 3). Mueller Hinton Broth was used as the test medium according to the NCCLS recommendations unless indicated otherwise. Table 2 shows the antimicrobial activity of the peptide analogues, which is clearly improved as compared to the parent peptide bolisin. The minimum inhibition concentrations are stated in [μg/ml].
  • TABLE 2
    Micro-
    organisms 1 2 3 4 5 6 7
    Bolisin* >300 >300 >300 >300 >300   >300 nd
    Bolisin >300 >300 >300 >300 >300   >300 >300  
    Bolisin** 25 300 300 6.25 150 150 nd
    BOL-6* 37.5 200 150 37.5     (9.375) 37.5 nd
    BOL-7* 75 >300 >300 150  (75) 300 nd
    BOL-11* 37.5 >300 >300 37.5 (150) 150 nd
    BOL-12* 18.75 >300 >300 18.75 (300) 200 nd
    BOL-13* 18.75 75 150 18.75     (9.375) 18.75 nd
    BOL-14* 50 >300 >300 37.5 (150) 75 nd
    BOL-15* 18.75 >300 >300 18.75 (150) 75 nd
    BOL-16* 100 >300 >300 75 (300) 150 nd
    BOL-17* 37.5 200 300 37.5 200 9.375 nd
    BOL-18* 18.75 >300 >300 18.75 300 37.5 nd
    BOL-21* 75 >300 >300 150 (150) 200 nd
    BOL-25* 150 >300 >300 150 (150) 200 nd
    BOL-27* 75 300 300 75 (150) 150 nd
    BOL-29* 9.375 75 150 9.375    (18.75) 50 nd
    BOL-30* 100 >300 >300 150 (300) 300 nd
    BOL-44 150 >300 200 200  (75) 75   37.5
    BOL-45 18.75 100 100 12.5  (25) 4.7    18.75
    BOL-46 300 200 200 200 (100) 150 150
    BOL-47 18.75 25 18.75 18.75  (25) 9.375    18.75
    BOL-48 9.375 12.5 9.375 18.75 200 4.7     9.375
       (6.5)
    BOL-49 75 25 18.75 50   (12.5) 18.75    18.75
    BOL-50 37.5 25 18.75 50    (6.25) 9.375     9.375
    BOL-51 37.5 25 12.5 50 300 18.75    (18.75)
     (25)
    BOL-52 300 200 200 >300   (37.5) 75   (37.5)
    BOL-53 150 200 200 200  (75) 100   (37.5)
    BOL-54 200 100 75 100  (25) 18.75    18.75
    BOL-55 12.5 50 37.5 12.5     (9.375) 3.125     9.375
    BOL-56 >300 >300 >300 >300 (200) 300 (300)
    BOL-57 >300 >300 >300 >300 (200) 300 300
    BOL-58 >300 >300 300 >300 (100) 100  (75)
    BOL-59 50 50 50 150    (18.75) 18.75     (9.375)
    BOL-60 50 25 50 100    (18.75) 18.75    (18.75)
    BOL-61 37.5 25 25 25 300 18.75     9.375
     (75)
    BOL-67 25 100 100 25  (50) 37.5    18.75
    BOL-68 200 200 300 200 (200) 300 200
    BOL-69 300 150 200 150 (200) 300   37.5
    BOL-70 100 150 150 100 (100) 75   37.5
    BOL-71 200 200 300 300 (200) 300 300
    BOL-72 75 25 18.75 100   (12.5) 18.75    18.75
    BOL-73 37.5 25 18.75 50     (9.375) 18.75     9.375
    BOL-74 300 150 150 300   (12.5) 18.75  75
    BOL-75 150 200 150 75   (37.5) 75   37.5
    BOL-79 9.375 >300 300 3.125    (4.7) 2.35    4.7
    BOL-80 >300 >300 >300 >300    (18.75) 150   37.5
    BOL-81 300 150 75 300    (18.75) 25  75
    BOL-82 18.75 75 37.5 18.75     (9.375) 12.5     9.375
    BOL-83 >300 >300 >300 >300 >300   >300 300
    BOL-84 >300 >300 300 >300  (75) 75   37.5
    BOL-85 >300 300 300 >300   (37.5) 150  75
    BOL-86 75 200 150 150    (18.75) 50    18.75
    BOL-87 9.375 37.5 9.375 18.75     (9.375) 9.375     9.375
    BOL-91 25 37.5 37.5 25 (150) 18.75 nd
    BOL-92 18.75 18.75 25 18.75   (37.5) 12.5 nd
    BOL-93 25 37.5 25 25   (37.5) 25 nd
    BOL-97 12.5 18.75 18.75 18.75   (37.5) 18.75 nd
    BOL-103 18.75 37.5 37.5 18.75    (9.4) 18.75 nd
    *Test medium: half-concentrated Mueller Hinton Broth
    **Test medium: 3 g/l Tryptic Soy Broth (low ion strength medium)
  • Values in parentheses designate a 75% inhibition of the growth of the microorganisms at the peptide concentration stated. A complete growth inhibition could not be achieved in this case. For determining the minimum inhibition concentration, the following microorganisms were used:
  • 1. Staphylococcus aureus ATCC 25923
  • 2. Enterococcus faecalis ATCC 51299 (vancomycin-resistant)
  • 3. Streptococcus pneumoniae DSM 11865 (penicillin-resistant)
  • 4. Escherichia coli ATCC 25922
  • 5. Pseudomonas aeruginosa ATCC 9027
  • 6. Klebsiella pneumoniae ATCC 10031
  • 7. Candida albicans ATCC 10231
  • The peptides according to the invention effectively inhibit the growth of both Gram-positive and Gram-negative bacteria as well as of yeasts. Human pathogens, such as Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae, were effectively killed. Of particular importance is the very effective growth inhibition of bacteria having an existing antibiotic-resistance, such as Streptococcus pneumoniae (penicillin-resistant) and Enterococcus faecalis (vancomycin-resistant). The potency of action of the bolisin analogues is manifoldly better than that of the parent peptide bolisin.
  • Examination of the Effectiveness at Increased Salt Concentration
  • Also for these examinations, the minimum inhibition concentration of the peptides against Gram-positive and Gram-negative microorganisms (microorganisms 1-6) was determined. Tryptic Soy Broth (3 g/l) with an addition of salt in physiological concentration (150 mM sodium chloride) was used as the test medium. Table 3 shows the antimicrobial activity of the peptide analogues in a salt-containing medium, which is also significantly improved over that of the parent peptide bolisin.
  • TABLE 3
    Micro-
    organisms 1 2 3 4 6
    Bolisin >300   >300   >300   >300 >300  
    BOL-44 200 (300) >300   150 >300  
    BOL-45   37.5 200 200 75    4.7
    BOL-46 >300   >300   >300   >300 >300  
    BOL-47    18.75  50   37.5 25     9.375
    BOL-48    18.75    18.75  25 9.375 9.375 b
    BOL-49  75  75 100 50  75
    BOL-50   37.5  50  50 37.5   37.5
    BOL-51  75   37.5   37.5 37.5  25
    BOL-52 >300   >300   >300   >300 (300)
    BOL-53 300 >300   >300 200 >300  
    BOL-54 300 300 300 200 (200)
    BOL-55    18.75 150 150 b 12.5    4.7
    BOL-56 >300   >300   >300   >300 >300  
    BOL-57 >300   >300   >300   >300 >300  
    BOL-58 >300   >300   >300   >300 >300  
    BOL-59  75 200 200 100 150
    BOL-60 100  75  75 75  50
    BOL-61    18.75  25   37.5 75    6.25
    BOL-67   37.5 150 150 75 9.375
    BOL-68 >300   >300   >300   >300 >300  
    BOL-69 300 >300   >300   150 >300  
    BOL-70 150 200 300 100 100
    BOL-71 >300   (300) >300   >300 >300  
    BOL-72  75  50  50 75  75
    BOL-73   37.5   37.5  75 b 50 150
    BOL-74 >300   300 >300   >300  75
    BOL-75 300 300 b 300 200 300
    BOL-79    4.7 >300   >300   4.7   <=1.56
    BOL-80 >300   >300   >300   >300 >300  
    BOL-81 (300) 200  (75) >300  50
    BOL-82    18.75  75  75 9.375    6.25
    BOL-83 >300   >300   >300   >300 >300  
    BOL-84 >300   >300   >300   >300 300
    BOL-85 >300   >300   >300   >300 >300  
    BOL-86 (300) >300   (300) >300 200
    BOL-87   37.5   37.5   37.5 25   37.5
  • Values in parentheses designate a 75% inhibition of the growth of the microorganisms at the peptide concentration stated. A complete growth inhibition could not be achieved in this case.
  • Examination of the cytotoxic activity of bolisin analogues
  • Bolisin analogues having a good antimicrobial activity against at least one of the seven strains of microorganisms tested (MIC ≦37.5 μg/ml) were selected for checking their cytotoxic activity.
  • In many cases, the ability of antimicrobial peptides to deposit on plasma membranes and permeabilize them is considered the mechanism of action of these substances. It is desirable that bacterial membranes are selectively damaged, whereas the cells of the host should remain unaffected. As a simple model for the examination of the cytotoxic effect of a peptide on eukaryotic cells, the hemolysis test is used in which the lysing and thus toxic activity of the peptides against red blood cells (erythrocytes) is examined. The procedure for determining the hemolytic activity of the peptides was performed by analogy with Helmerhorst et al. (Helmerhorst et al., 1999, FEBS Lett. 449: 105-110).
  • Erythrocytes were isolated from the citrate-containing whole blood of a healthy subject by centrifugation (1500×g, 20° C., 10 min) and diluted 200 fold with test medium. Peptides were added at various concentrations to a 96 well microtitration plate with V-shaped bottoms and incubated with the diluted erythrocyte suspension at 37° C. for 1 h. The erythrocytes were separated by a subsequent centrifugation (1000×g for 5 min). The supernatants colored from released hemoglobin were transferred to a 96 well microtitration plate with flat bottoms, and its absorption was determined at a wavelength of λ=450 nm in a microtitration plate reader. Incubation with a 1% solution of the surfactant Tween-20 served as a reference value for 100% hemolysis. Erythrocytes incubated only with test medium served as the negative control.
  • The hemolytic activity of bolisin analogues was stated on the basis of the total hemolysis by Tween-20 and calculated by the following formula:

  • Hemolysis [%]=[A 450 nm (peptide)−A 450 nm (negative control)]/[A 450 nm (1% Tween 20)−A 450 nm (negative control)]*100
  • TSB medium with 287 mM glucose served as the test medium. The isotonic glucose concentration is to prevent non-specific hemolysis in a hypotensive medium (osmoprotection).
  • It is desirable that the peptides according to the invention exhibit no or but moderate lytic properties against erythrocytes. “Moderate lytic properties” means a lysis of less than 30% of the erythrocytes for the application of antimicrobially effective peptide concentrations.
  • FIG. 1 shows that bolisin analogues in antimicrobially effective concentrations do not cause any hemolysis worth mentioning (<5%). Even at high concentrations (500 μg/ml), only a moderate lytic activity can be established (<30%). For comparison, the hemolytic activity of the antimicrobial peptide MBI-28 (Gough et al., 1996, Infect. Immun. 64(12): 4922-7) was plotted.

Claims (19)

1-19. (canceled)
20: Artificial peptide selected from the group consisting of SEQ ID NOS: 1-42 and 44-56.
21: The peptide of claim 20 conjugated with a polymer.
22: The peptide of claim 20 conjugated with polysorbate.
23: A medicament comprising an antibiotically effective amount of the peptide of claim 20 in combination with a pharmacologically acceptable carrier or diluent.
24: A medicament comprising an antibiotically effective amount of the peptide of claim 21 in combination with a pharmacologically acceptable carrier or diluent.
25: A medicament comprising an antibiotically effective amount of the peptide of claim 22 in combination with a pharmacologically acceptable carrier or diluent.
26: The medicament according to claim 23 further comprising at least one ingredient, wherein the at least one ingredient is (i) an additional antibiotically effective ingredient (ii) an antivirally effective ingredient, an antiparasitically effective ingredient, or an antifungally effective ingredient.
27: The medicament according to claim 23 in an application form selected from the group consisting of an infusion, ointment, tablet, spray, and slow release capsule.
28: The medicament according to claim 24 in an application form selected from the group consisting of an infusion, ointment, tablet, spray, and slow release capsule.
29: A diagnostic agent comprising an effective amount of the peptide of claim 20 in combination with a pharmacologically acceptable carrier or diluent.
30: A diagnostic agent comprising an effective amount of the peptide of claim 21 in combination with a pharmacologically acceptable carrier or diluent.
31: A diagnostic agent comprising an effective amount of the peptide of claim 22 in combination with a pharmacologically acceptable carrier or diluent.
32: A foodstuff incorporating the peptide of claim 20.
33: A method for inhibiting the growth of a microorganism comprising contacting the microorganism with an antimicrobially effective amount of the peptide of claim 20.
34: A method for inhibiting the growth of a microorganism comprising contacting the microorganism with an antimicrobially effective amount of the peptide of claim 21.
35: A method for inhibiting the growth of a microorganism comprising contacting the microorganism with an antimicrobially effective amount of the peptide of claim 22.
36: A process for preparing the peptide according to claim 20 comprising expressing the protein in a prokaryotic or eukaryotic organism or chemically synthesizing the protein.
37: A method of using the peptide of claim 20 comprising administering an antimicrobially effective amount of the peptide to a patient in need thereof.
US12/289,180 2001-12-07 2008-10-22 Novel antimicrobial bolisin peptides Abandoned US20090149391A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/289,180 US20090149391A1 (en) 2001-12-07 2008-10-22 Novel antimicrobial bolisin peptides

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01129094 2001-12-07
DE01129094.7 2001-12-07
PCT/EP2002/013724 WO2003048201A1 (en) 2001-12-07 2002-12-04 Antimicrobial bolisin peptides
US10/497,909 US7449545B2 (en) 2001-12-07 2002-12-04 Antimicrobial bolisin peptides
US12/289,180 US20090149391A1 (en) 2001-12-07 2008-10-22 Novel antimicrobial bolisin peptides

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/497,909 Division US7449545B2 (en) 2001-12-07 2002-12-04 Antimicrobial bolisin peptides
PCT/EP2002/013724 Division WO2003048201A1 (en) 2001-12-07 2002-12-04 Antimicrobial bolisin peptides

Publications (1)

Publication Number Publication Date
US20090149391A1 true US20090149391A1 (en) 2009-06-11

Family

ID=8179461

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/497,909 Expired - Fee Related US7449545B2 (en) 2001-12-07 2002-12-04 Antimicrobial bolisin peptides
US12/289,180 Abandoned US20090149391A1 (en) 2001-12-07 2008-10-22 Novel antimicrobial bolisin peptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/497,909 Expired - Fee Related US7449545B2 (en) 2001-12-07 2002-12-04 Antimicrobial bolisin peptides

Country Status (8)

Country Link
US (2) US7449545B2 (en)
EP (1) EP1453855B1 (en)
JP (1) JP2005532784A (en)
AT (1) ATE423132T1 (en)
AU (1) AU2002358605A1 (en)
DE (1) DE50213300D1 (en)
ES (1) ES2320867T3 (en)
WO (1) WO2003048201A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008132737A1 (en) 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Novel antimicrobial agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4444753C2 (en) 1994-12-15 1998-08-06 Forssmann Wolf Georg Antibiotic peptides from bovine milk, their production and use
EP0889902B1 (en) 1996-03-25 2001-06-20 Pharis Biotec GmbH Antibiotic peptides from bovine milk
WO2001094386A2 (en) 2000-06-08 2001-12-13 Ipf Pharmaceuticals Gmbh Method for the extraction and the use of antibiotically effective peptides for treating infectious diseases

Also Published As

Publication number Publication date
ES2320867T3 (en) 2009-05-29
EP1453855B1 (en) 2009-02-18
US20060252915A1 (en) 2006-11-09
ATE423132T1 (en) 2009-03-15
EP1453855A1 (en) 2004-09-08
US7449545B2 (en) 2008-11-11
DE50213300D1 (en) 2009-04-02
WO2003048201A1 (en) 2003-06-12
AU2002358605A1 (en) 2003-06-17
JP2005532784A (en) 2005-11-04

Similar Documents

Publication Publication Date Title
US9227999B2 (en) Antimicrobial cationic peptides and formulations thereof
US9872885B2 (en) Antimicrobial and anti-inflammatory peptides
AU2002324752A1 (en) Antimicrobial cationic peptides and formulations thereof
KR101896927B1 (en) An anti-microbial peptide, Protaetiamycine 1 isolated from Protaetia brevitarsis seulensis and its synthetic composition
CA2319094C (en) Antimicrobial peptides
KR20210007075A (en) Novel antimicrobial peptide derived from antimicrobial peptides isolated from Korean sea cucumber and uses thereof
KR101700603B1 (en) An anti-microbial peptide, Periplanetasin-1 isolated from Periplaneta americana and its synthetic composition
KR20200144066A (en) Romo1-derived antimicrobial peptides containing lysine substitution and variants thereof
KR101953834B1 (en) An anti-microbial peptide, Teleogryllusine 2 isolated from Teleogryllus emma and its synthetic composition
US7449545B2 (en) Antimicrobial bolisin peptides
KR101686428B1 (en) An anti-microbial peptide, Periplanetasin-2 isolated from Periplaneta americana and its synthetic composition
KR102039400B1 (en) Novel antimicrobial peptide derived from mBjAMP1 peptide and uses thereof
US11117931B2 (en) Antimicrobial peptide derived from Hp1404 peptide and uses thereof
KR20170131909A (en) An anti-microbial peptide, Oxyasin-3 isolated from Oxya chinensis sinuosa and its synthetic composition
KR101889404B1 (en) An anti-microbial peptide, Periplanetasin-5 isolated from Periplaneta americana and its synthetic composition
KR101851134B1 (en) An anti-microbial peptide, Periplanetasin-6 isolated from Periplaneta americana and its synthetic composition
US20230181678A1 (en) Novel antibacterial peptide or peptide analog and use thereof
DE10160170A1 (en) New antimicrobial peptides, useful clinically and as preservatives for e.g. foods or cosmetics, are derived from bolisin, also related nucleic acids and mimetics
KR101889403B1 (en) An anti-microbial peptide, Periplanetasin-4 isolated from Periplaneta americana and its synthetic composition
JPH06199893A (en) New peptide and antimicrobial agent

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION